Quick Facts
  • Primary Location:
    Hollings Cancer Center at the Medical University of South Carolina
  • Expertise:
    Laboratory Research
    Clinical Trials
    Non-Small Cell Lung Cancer
    Immunotherapy
  • Speciality:
    Thoracic Oncology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    Tulane University School of Medicine

Get to Know Dr. John Wrangle

Medical oncologist Dr. John Wrangle is an innovator whose research laboratory at the Medical University of South Carolina is playing a major role in advancing the use of novel immunotherapy combinations with groundbreaking clinical trials.

Wrangle treats patients with lung cancer, esophageal cancer and malignant pleural mesothelioma.

Work in the Wrangle Research Laboratory led to the immunotherapy combination of pembrolizumab and N-803 being used as part of an ongoing, 700-site clinical trial orchestrated by the National Cancer Institute for the treatment of non-small cell lung cancer.

Wrangle plays a key role in the Lung and Thoracic Cancer Program at the Medical University of South Carolina, the state’s only NCI-designated cancer center. It is recognized for its high treatment standards involving a multidisciplinary collaboration of specialists.

Treatment options may include a combination of surgery and chemotherapeutic and targeted agents based on individual molecular characteristics.

Contact John Wrangle
By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

Specialties of Dr. John Wrangle

  • Oncology
  • Hematology
  • Lung cancer
  • Esophageal cancer
  • Pleura mesothelioma
  • Immunotherapy
  • Chemotherapy
  • Targeted therapy

Dr. John Wrangle’s Experience and Education

  • Medical University of South Carolina Hollings Cancer Center
  • Johns Hopkins Hospital (Fellowship)
  • Emory University School of Medicine (Residency)
  • Tulane University School of Medicine (M.D.)

Awards and Certifications

  • Board certified in internal medicine
  • Board certified in medical oncology
  • Smart State Burtschy Family Distinguished Endowed Chair in Lung Cancer Research

Publications of Dr. John Wrangle

  • Alexander, M. & Wrangle, J. (2020, November 1). Can We MIRror the Efficacy of Immune Checkpoints With miRNAs? Journal of Thoracic Oncology.
  • Yoshida, A. et al. (2019, September 18). SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances.
  • Wrangle, J.M. et al. (2018, May). ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomized, open-label, phase 1b trial. Lancet Oncology.
  • Wrangle, J.M. et al. (2018, February 1). IL-2 and Beyond in Cancer Immunotherapy. Journal of Interferon & Cytokine Research.
  • Dimou, A., Sherman, C. & Wrangle, J. (2016, July). Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. Journal of Thoracic Imaging.
man and his wife looking at computer together watching webinar from the mesothelioma center
Browse Our Free Mesothelioma Webinars
Access More than $32 Billion in Trust Funds
Scientist is laboratory studying cells under a microscope
Find Active Mesothelioma Clinical Trials